Pfizer Inc. has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing its beneficial ownership of 2,062,236,079 Ordinary Shares of Haleon plc, which represents approximately 22.6% of Haleon's outstanding Ordinary Shares. This position includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing, dated March 21, 2024, follows the completion of a secondary offering and a share buyback, where Haleon repurchased 102,272,727 Ordinary Shares from Pfizer at a price of £3.08 per share, amounting to approximately £315 million. The secondary offering and share buyback were both closed on March 21, 2024. Pfizer has also entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. This amendment, Amendment No. 7, updates previous filings and provides the latest details on Pfizer's holdings and agreements with Haleon plc.

Pfizer Inc. has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission, disclosing its beneficial ownership of 2,062,236,079 Ordinary Shares of Haleon plc, which represents approximately 22.6% of Haleon's outstanding Ordinary Shares. This position includes both restricted American Depositary Shares and Ordinary Shares held by Pfizer's nominee. The filing, dated March 21, 2024, follows the completion of a secondary offering and a share buyback, where Haleon repurchased 102,272,727 Ordinary Shares from Pfizer at a price of £3.08 per share, amounting to approximately £315 million. The secondary offering and share buyback were both closed on March 21, 2024. Pfizer has also entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. This amendment, Amendment No. 7, updates previous filings and provides the latest details on Pfizer's holdings and agreements with Haleon plc.